Literature DB >> 33207030

Stereotactic radiotherapy of appropriately selected meningiomas and metastatic brain tumor beds with gamma knife icon versus volumetric modulated arc therapy.

Jacob S Buatti1, John M Buatti1, Sridhar Yaddanapudi1, Edward C Pennington1, Dongxu Wang1, Brandie Gross1, Joël J St-Aubin1, Daniel E Hyer1, Mark C Smith1, Ryan T Flynn1.   

Abstract

PURPOSE: To determine if the gamma knife icon (GKI) can provide superior stereotactic radiotherapy (SRT) dose distributions for appropriately selected meningioma and post-resection brain tumor bed treatments to volumetric modulated arc therapy (VMAT).
MATERIALS AND METHODS: Appropriately selected targets were not proximal to great vessels, did not have sensitive soft tissue including organs-at-risk (OARs) within the planning target volume (PTV), and did not have concave tumors containing excessive normal brain tissue. Four of fourteen candidate meningioma patients and six of six candidate patients with brain tumor cavities were considered for this treatment planning comparison study. PTVs were generated for GKI and VMAT by adding 1 mm and 3 mm margins, respectively, to the GTVs. Identical PTV V100% -values were obtained for the GKI and VMAT plans for each patient. Meningioma and tumor bed prescription doses were 52.7-54.0 in 1.7-1.8 Gy fractions and 25 Gy in 5 Gy fractions, respectively. GKI dose rate was 3.735 Gy/min for 16 mm collimators.
RESULTS: PTV radical dose homogeneity index was 3.03 ± 0.35 for GKI and 1.27 ± 0.19 for VMAT. Normal brain D1% , D5% , and D10% were lower for GKI than VMAT by 45.8 ± 10.9%, 38.9 ± 11.5%, and 35.4 ± 16.5% respectively. All OARs considered received lower maximum doses for GKI than VMAT. GKI and VMAT treatment times for meningioma plans were 12.1 ± 4.13 min and 6.2 ± 0.32 min, respectively, and, for tumor cavities, were 18.1 ± 5.1 min and 11.0 ± 0.56 min, respectively.
CONCLUSIONS: Appropriately selected meningioma and brain tumor bed patients may benefit from GKI-based SRT due to the decreased normal brain and OAR doses relative to VMAT enabled by smaller margins. Care must be taken in meningioma patient selection for SRT with the GKI, even if they are clinically appropriate for VMAT.
© 2020 The Authors. Journal of Applied Clinical Medical Physics published by Wiley Periodicals, Inc. on behalf of American Association of Physicists in Medicine.

Entities:  

Keywords:  gamma knife; meningioma; stereotactic radiotherapy; tumor bed; volumetric modulated arc therapy

Mesh:

Year:  2020        PMID: 33207030      PMCID: PMC7769414          DOI: 10.1002/acm2.13100

Source DB:  PubMed          Journal:  J Appl Clin Med Phys        ISSN: 1526-9914            Impact factor:   2.102


  14 in total

1.  Commissioning of the Leksell Gamma Knife® Icon™.

Authors:  Michele Zeverino; Maud Jaccard; David Patin; Nick Ryckx; Maud Marguet; Constantin Tuleasca; Luis Schiappacasse; Jean Bourhis; Marc Levivier; Francois O Bochud; Raphaël Moeckli
Journal:  Med Phys       Date:  2017-01-30       Impact factor: 4.071

2.  Dosimetric characterization of hypofractionated Gamma Knife radiosurgery of large or complex brain tumors versus linear accelerator-based treatments.

Authors:  Peng Dong; Angélica Pérez-Andújar; Dilini Pinnaduwage; Steve Braunstein; Philip Theodosopoulos; Michael McDermott; Penny Sneed; Lijun Ma
Journal:  J Neurosurg       Date:  2016-12       Impact factor: 5.115

3.  Benign meningiomas: primary treatment selection affects survival.

Authors:  K S Condra; J M Buatti; W M Mendenhall; W A Friedman; R B Marcus; A L Rhoton
Journal:  Int J Radiat Oncol Biol Phys       Date:  1997-09-01       Impact factor: 7.038

4.  Impact of millimeter-level margins on peripheral normal brain sparing for gamma knife radiosurgery.

Authors:  Lijun Ma; Arjun Sahgal; David A Larson; Dilini Pinnaduwage; Shannon Fogh; Igor Barani; Jean Nakamura; Michael McDermott; Penny Sneed
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-05-01       Impact factor: 7.038

5.  Validation of frame-based positioning accuracy with cone-beam computed tomography in Gamma Knife Icon radiosurgery.

Authors:  Florian Stieler; Frederik Wenz; Beate Schweizer; Martin Polednik; Frank Anton Giordano; Sabine Mai
Journal:  Phys Med       Date:  2018-07-06       Impact factor: 2.685

6.  Validity of the use of nose tip motion as a surrogate for intracranial motion in mask-fixated frameless Gamma Knife® Icon™ therapy.

Authors:  Gavin Wright; Natalie Harrold; Paul Hatfield; Peter Bownes
Journal:  J Radiosurg SBRT       Date:  2017

7.  Simulational study of a dosimetric comparison between a Gamma Knife treatment plan and an intensity-modulated radiotherapy plan for skull base tumors.

Authors:  Hisato Nakazawa; Yoshimasa Mori; Masataka Komori; Takahiko Tsugawa; Yuta Shibamoto; Tatsuya Kobayashi; Chisa Hashizume; Yukio Uchiyama; Masahiro Hagiwara
Journal:  J Radiat Res       Date:  2013-12-17       Impact factor: 2.724

8.  Fractionated SRT using VMAT and Gamma Knife for brain metastases and gliomas--a planning study.

Authors:  Marie Huss; Pierre Barsoum; Ernest Dodoo; Georges Sinclair; Iuliana Toma-Dasu
Journal:  J Appl Clin Med Phys       Date:  2015-11-08       Impact factor: 2.102

9.  Evaluation of stability of stereotactic space defined by cone-beam CT for the Leksell Gamma Knife Icon.

Authors:  Ismail AlDahlawi; Dheerendra Prasad; Matthew B Podgorsak
Journal:  J Appl Clin Med Phys       Date:  2017-04-17       Impact factor: 2.102

10.  Clinical outcome after particle therapy for meningiomas of the skull base: toxicity and local control in patients treated with active rasterscanning.

Authors:  Rami A El Shafie; Maja Czech; Kerstin A Kessel; Daniel Habermehl; Dorothea Weber; Stefan Rieken; Nina Bougatf; Oliver Jäkel; Jürgen Debus; Stephanie E Combs
Journal:  Radiat Oncol       Date:  2018-03-27       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.